UCB nabs bigger market for seizure med Vimpat; AZ's Brilinta safe for ambulance use, but not more beneficial;

@FiercePharma: ICYMI: Are specialty pharma CEOs worth their salt? Story | Follow @FiercePharma

@EricPFierce: Pablo Manuel Fernandez is on the the FDA Most Wanted list. He sold $12M worth of counterfeit Viagra. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Are specialty pharma CEOs worth their salt? More | Follow @CarlyHFierce

> UCB won broader approval for its epilepsy drug Vimpat as monotherapy for patients with partial-onset seizures; it's already approved as an add-on in these patients, but the new indication covers a much larger market. Report

> AstraZeneca's ($AZN) bloodthinner Brilinta is safe to use in heart attack victims during transport to the hospital, but this early use didn't offer any added benefit to later use. Report

> Johnson & Johnson ($JNJ) and Bayer's anticoagulant drug Xarelto is a solid alternative to warfarin in atrial fibrillation patients undergoing cardioversion to return their heart rhythm to normal, a study found. Report

> Denmark's Lundbeck rolled out its neurological drug Northera in the U.S. after approval by the FDA. Report

> New concerns about a Servier heart rate drug arose in a new study, which found that patients with a severe form of angina did worse when using the med. Report

> Hospital admissions for skin cancer soared by 41% in England over the past 5 years, a study found, with a 30% increase in cases of the most deadly form, melanoma. Report

Medical Device News

@FierceMedDev: ICYMI: looks to sell off Cordis for as much as $2B. Article | Follow @FierceMedDev

@VarunSaxena2: Attorney: Latest UDI guidance unhelpful, many questions left unanswered. Story | Follow @VarunSaxena2

@MichaelGFierce: Organic nanoparticles offer 'complete package' against cancer: delivery and imaging. FierceDrugDelivery story | Follow @MichaelGFierce

> Boston Scientific faces stinging setback for vagus nerve stimulation device in mid-stage trial. Story

> Dime-sized device can separate healthy and cancerous cells. Article

> Can the nose bone be connected to the knee bone? More

Biotech News

@FierceBiotech: Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump. Report | Follow @FierceBiotech

@JohnCFierce: ICYMI: Novartis' LCZ696 kindles megablockbuster projections with impressive PhIII heart data. Article | Follow @JohnCFierce

@EmilyMFierce: On-off switch found for natural antibiotics maker. Story | Follow @EmilyMFierce

> Acadia surges after nabbing 'breakthrough' title for late-stage Parkinson's drug. News

> Novo Nordisk abandons anti-inflammatory R&D work, spotlights diabetes, obesity. Article

> Cabozantinib flops against prostate cancer, forcing big jobs cuts at Exelixis. Report

CRO News

> Synexus snags another South African site and widens its footprint. Report

> Cenix lands an early-phase deal with BASF's Metanomics. News

> CRO Onyx signs up to help CRUK handle cancer R&D. More

> PRA sets sights on a new HQ. Story

> Catalent lends its weight to an armed-antibody cancer candidate. Article

Biotech IT News

> J&J, Sanofi apply IBM's Watson to R&D. News

> Takeda strikes deal with C4X to access 3D drug structure tech. Article

> Apple tightens health data privacy rules ahead of HealthKit launch. More

> Hackers target pharma's 'golden nuggets' to steal a lead in R&D. Story

> Amazon's meeting with FDA starts the rumor mill turning. Item

Animal Health News

> Boehringer to stay focused on porcine type 2 vaccine; dropping its RTU program. News

> Survey: Midwest corridor is a global magnet for animal health companies. Report

> Could a pair of offerings be the first signs of animal health IPO momentum? Article

> Mars Petcare issues four-state recall for 22 bags of Pedigree dog food. Story

> New Zealand's Simcro to set up North American HQ in Kansas. More

Biotech Research News

> Japanese institute to cut back stem cell research in wake of scandal. More

> Japanese institute to cut back stem cell research in wake of scandal. Report

> Gene therapy prevents botulism in mice. Article

> ZMapp antibody therapy prevents Ebola infection in monkeys. Item

> Canadian Immunovaccine reports positive preclinical data for Ebola vaccine. Story

Pharma Manufacturing News

> Indian drugmakers giving up 'advantage' to move to higher-margin drugs. More

> Adcock shareholder on defense for opposing buyout by CFR. News

> Could a pair of offerings be the first signs of animal health IPO momentum? More

> Boehringer Ingelheim recalls cancer drug made at ill-fated Bedford plant. Story

> Sources: West Pharmaceutical looks at $130M investment in Ireland. Article

And Finally... In lowering blood pressure and controlling blood sugar, there is such a thing as too much treatment. Report (sub. req.)

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.